Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment.
Soo Min AhnJonggi ChoiByong Duk YeSuk-Kyun YangJi-Seon OhYong-Gil KimChang-Keun LeeBin YooSang Hyoung ParkSeokchan HongPublished in: Gut and liver (2021)
The risk of HBV reactivation was not significantly associated with the timing of biologics administration after anti-HBV treatment. Thus, biologics may be initiated early in patients with IMID undergoing treatment for HBV.
Keyphrases